Interestingly, the post-treatment tumors showed more staining for nuclear localized MMR proteins MSH2, MSH6 and PMS2 than the untreated tumor (Fig. 6C), which can be taken to indicate enhancement of MMR capacity of vemurafenib treated tumors. This evidence concerns the gene MSH2 and neoplasm.